Bioheart to Change Name to U.S. Stem Cell, Inc.; SEC Approval for Reverse Stock Split Filed

Management believes that the reverse stock split will elevate the Company from its current “penny stock” position enabling institutional investors who are precluded from investing in companies below certain price per share ranges to potentially consider …

[Read the full article here]

Comments are closed.